Erd2 Inhibitors
Chemical inhibitors of Erd2 target various aspects of the protein's function related to protein trafficking between the endoplasmic reticulum and the Golgi apparatus. Brefeldin A disrupts the protein's operation by blocking the transport process crucial for Erd2's role, resulting in a functional blockade of protein sorting and signaling. Similarly, Exo2 compromises Erd2's activity by dismantling the Golgi structure, undermining the protein's localization and thereby its function in trafficking. Monensin alters the ion gradient in the Golgi and endoplasmic reticulum, which is critical for protein maturation and trafficking, processes that are integral to Erd2's role. Ilomastat, though primarily targeting matrix metalloproteinases, can incidentally inhibit Erd2 by affecting extracellular matrix remodeling, which in turn might alter cellular signaling pathways that involve Erd2.
Additionally, Swainsonine and Castanospermine exert their inhibitory effects by interfering with glycosylation processes in the Golgi and endoplasmic reticulum, respectively. Since glycosylation is essential for the proper sorting and trafficking of proteins, these inhibitors can disrupt the functioning of Erd2. Deoxynojirimycin also impairs glycosylation by inhibiting alpha-glucosidases in the endoplasmic reticulum, indirectly affecting Erd2's trafficking role. Nocodazole and Colchicine both disrupt microtubule polymerization, which is essential for vesicle movement and protein trafficking, thereby impeding Erd2's activity. Tunicamycin blocks the initial step of N-linked glycosylation, undercutting the maturation and trafficking of proteins, which are critical for Erd2 function. Forskolin, by increasing intracellular cAMP, can alter signaling pathways and cellular processes where Erd2 is engaged, leading to an indirect inhibition of Erd2's role in protein trafficking. Lastly, Cytochalasin D, an actin polymerization inhibitor, can impede the cytoskeletal dynamics crucial for Erd2's vesicular trafficking functions.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits Erd2 by disrupting the protein's function in the Golgi apparatus, leading to a blockade of transport between the endoplasmic reticulum and the Golgi, which is essential for Erd2's role in protein trafficking. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $87.00 $282.00 | 1 | |
Exo2 functions as an inhibitor of Erd2 by causing disassembly of the Golgi structure, indirectly leading to impaired Erd2 function due to the disruption of its subcellular localization and processing environment. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is a polyether antibiotic that inhibits Erd2 by altering the ion gradient in the Golgi and endoplasmic reticulum, where Erd2 operates, thus affecting the protein maturation and trafficking processes that are crucial for Erd2's function. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
Ilomastat, while primarily a matrix metalloproteinase inhibitor, can indirectly inhibit Erd2 by altering the extracellular matrix remodeling, which may affect the cellular signaling pathways and vesicular trafficking routes that involve Erd2. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits Erd2 indirectly by inhibiting Golgi alpha-mannosidase II, which is crucial for proper glycosylation, a process in which Erd2 is indirectly involved through its role in protein trafficking. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine inhibits Erd2 by inhibiting glucosidases involved in the glycosylation process in the endoplasmic reticulum, thereby indirectly affecting the protein processing and trafficking that Erd2 mediates. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Deoxynojirimycin acts as an inhibitor of alpha-glucosidases within the endoplasmic reticulum, indirectly inhibiting Erd2 by disrupting the glycosylation process which is essential for the proper functioning of Erd2 in protein trafficking. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubule polymerization, thereby inhibiting Erd2 indirectly by interfering with the cytoskeletal dynamics and vesicular transport mechanisms that are essential for Erd2's role in protein sorting and trafficking. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine binds to tubulin and inhibits microtubule polymerization, which indirectly inhibits Erd2 by disrupting the cytoskeletal structure necessary for vesicle movement and protein trafficking, where Erd2 is involved. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the first step in the biosynthetic pathway. This indirectly inhibits Erd2 by disrupting the protein maturation and trafficking processes that are crucial for Erd2's role. | ||||||